Alteration of the intestinal microbiome: Fecal microbiota transplant and probiotics for Clostridium difficile and beyond

Expert Review of Gastroenterology and Hepatology

Volumn 7, Issue 7, 2013, Pages 615-628

  Vindigni, Stephen M ^a   Broussard, Elizabeth K ^a   Surawicz, Christina M ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Clostridium difficile; Fecal microbiota transplant; Intestinal microbiome; Probiotics

Indexed keywords

ENEMA; PROBIOTIC AGENT;

ALLERGIC DISEASE; BIOLOGICAL THERAPY; CARDIOVASCULAR DISEASE; CHRONIC CONSTIPATION; CLINICAL EFFECTIVENESS; CLOSTRIDIUM DIFFICILE INFECTION; COLONOSCOPY; CROHN DISEASE; DONOR SELECTION; FECAL MICROBIOTA TRANSPLANTATION; HUMAN; INTESTINE FLORA; IRRITABLE COLON; NASOGASTRIC TUBE; NEUROLOGIC DISEASE; NONHUMAN; PATIENT SAFETY; REVIEW; RISK FACTOR; ULCERATIVE COLITIS; ANIMAL; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FECES; INTESTINE; MICROBIOLOGY; MICROFLORA; PATHOGENICITY; PEPTOCLOSTRIDIUM DIFFICILE; PROCEDURES; RECURRENT DISEASE; TREATMENT OUTCOME; CLOSTRIDIUM DIFFICILE; METHODOLOGY; PSEUDOMEMBRANOUS COLITIS;

ANIMALS; BIOLOGICAL THERAPY; CLOSTRIDIUM DIFFICILE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FECES; HUMANS; INTESTINES; MICROBIOTA; PROBIOTICS; RECURRENCE; TREATMENT OUTCOME;

EID: 84887993145     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/17474124.2013.832501     Document Type: Review

References (155)

1. Surawicz CM, Brandt LJ, Binion DG et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am. J. Gastroenterol. 108(4), 478-98 (2013)
2. Borody TJ, Khoruts A. Fecal microbiota transplantation and emerging applications. Nat. Rev. Gastroenterol. Hepatol. 9, 88-96 (2012).
3. Jarvis WR, Schlosser J, Jarvis AA, Chinn RY. National point prevalence of Clostridium difficile in US health care facility inpatients, 2008. Am. J. Infect. Control. 37(4), 263-270 (2009).
4. Agito MD, Atreja A, Rizk MK. Fecal microbiota transplantation for recurrent C difficile infection: Ready for prime time? Cleve. Clin. J. Med. 80(2), 101-108 (2013).
5. Bakken JS. Fecal bacteriotherapy for recurrent Clostridium difficile infection. Anaerobe 15(6), 285-289 (2009).
6. Bakken JS, Borody T, Brandt LJ et al. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin. Gastroenterol. Hepatol. 9(12), 1044-1049 (2011).
7. Brandt LJ, Reddy SS. Fecal microbiota transplantation for recurrent Clostridium difficile infection. J. Clin. Gastroenterol. S159-S167 (2011).
8. Zhang F, Luo W, Shi Y, Fan Z, Ji G. Should we standardize the 1, 700-year-old fecal microbiota transplantation? Am. J. Gastroenterol. 1755, author reply 1755-1756 (2012).
9. Borody TJ, Warren EF, Leis SM, Surace R, Ashman O, Siarakas S. Bacteriotherapy using fecal flora: toying with human motions. J. Clin. Gastroenterol. 38(6), 475-483 (2004).
10. Eiseman B, Silen W, Bascom GS, Kauvar AJ. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery 44(5), 854-859 (1958).
11. Brandt LJ, Aroniadis OC, Mellow M et al. Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection. Am. J. Gastroenterol. 1079-1087 (2012).
12. Khoruts A, Dicksved J, Jansson JK, Sadowsky MJ. Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile-associated diarrhea. J. Clin. Gastroenterol. 44(5), 354-360 (2010).
13. Chang JY, Antonopoulos DA, Kalra A et al. Decreased diversity of the fecal microbiome in recurrent Clostridium difficile-associated diarrhea. J. Infect. Dis. 197(3), 435-438 (2008).
14. Tvede M, Rask-Madsen J. Bacteriotherapy for chronic relapsing Clostridium difficile diarrhoea in six patients. Lancet 1(8648), 1156-1160 (1989).
15. Aas J, Gessert CE, Bakken JS. Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin. Infect. Dis. 36(5), 580-585 (2003).
16. Yoon SS, Brandt LJ. Treatment of refractory/ recurrent C. difficile-associated disease by donated stool transplanted via colonoscopy: a case series of 12 patients. J. Clin. Gastroenterol. 44(8), 562-566 (2010).
17. Kelly CR, de Leon L, Jasutkar N. Fecal microbiota transplantation for relapsing Clostridium difficile infection in 26 patients: methodology and results. J. Clin. Gastroenterol. 46(2), 145-149 (2012).
18. Bowden TA, Mansberger AR, Lykins LE. Pseudomembraneous enterocolitis: mechanism for restoring floral homeostasis. Am. Surg. 47(4), 178-183 (1981).
19. Schwan A, Sjölin S, Trottestam U, Aronsson B. Relapsing Clostridium difficile enterocolitis cured by rectal infusion of normal faeces. Scand. J. Infect. Dis. 16(2), 211-215 (1984).
20. Persky SE, Brandt LJ. Treatment of recurrent Clostridium difficile-associated diarrhea by administration of donated stool directly through a colonoscope. Am. J. Gastroenterol. 95(11), 3283-3285 (2000).
21. MacConnachie AA, Fox R, Kennedy DR, Seaton RA. Faecal transplant for recurrent Clostridium difficile-associated diarrhoea: a UK case series. QJM 102(11) 781-784 (2009).
22. Garborg K, Waagsbo B, Stallemo A, Matre J, Sundoy A. Results of faecal donor instillation therapy for recurrent Clostridium difficile-associated diarrhoea. Scand. J. Infect. Dis. 42(11-12), 857-861 (2010).
23. Mellow MH, Kanatzar A. Colonoscopic fecal bacteriotherapy in the treatment of recurrent Clostridium difficile infection - results and follow-up. J. Okla. State Med. Assoc. 104(3), 89-91 (2011).
24. Rohlke F, Surawicz CM, Stollman N. Fecal flora reconstitution for recurrent Clostridium difficile infection: results and methodology. J. Clin. Gastroenterol. 44(8), 567-570 (2010).
25. Silverman MS, Davis I, Pillai DR. Success of self-administered home fecal transplantation for chronic Clostridium difficile infection. Clin. Gastroenterol. Hepatol. 8(5), 471-473 (2010).
26. Mattila E, Uusitalo-Seppala R, Wuorela M et al. Fecal transplantation, through colonoscopy, is effective therapy for recurrent Clostridium difficile infection. Gastroenterology 142(3), 490-496 (2012).
27. Rubin TA, Gessert CE, Aas J, Bakken JS. Fecal microbiome transplantation for recurrent Clostridium difficile infection: Report on a case series. Anaerobe 19, 22-26 (2013).
28. Hamilton MJ, Weingarden AR, Sadowsky MJ, Khoruts A. Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection. Am. J. Gastroenterol. 107(5), 761-767 (2012).
29. van Nood E, Vrieze A, Nieuwdorp M et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N. Engl. J. Med. 368(5), 407-415 (2013).
30. Guo B, Harstall C, Louie T, Veldhuyzen van Zanten S, Dieleman LA. Systematic review: faecal transplantation for the treatment of Clostridium difficile-associated disease. Aliment. Pharmacol. Ther. 35(8), 865-875 (2012).
31. Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin. Infect. Dis. 994-1002 (2011).
32. Owens C, Broussard E, Surawicz C. Fecal Microbiota Transplantation and Donor Standardization. Trends Microbiol. (2013) (In Press).
33. Kleger A, Schnell J, Essig A et al. Fecal Transplant in Refractory Clostridium difficile Colitis. Dtsch. Arztebl. Int. 110(7), 108-115 (2013).
34. You DM, Franzos MA, Holman RP. Successful treatment of fulminant Clostridium difficile infection with fecal bacteriotherapy. Ann. Intern. Med. 148(8), 632-633 (2008).
35. Fenton S, Stephenson D, Weder C. Pseudomembranous colitis associated with antibiotic therapy - an emerging entity. Can. Med. Assoc. J. 111(10), 1110-1111, 1114 (1974).
36. Kassam Z, Hundal R, Marshall JK, Lee CH. Fecal transplant via retention enema for refractory or recurrent Clostridium difficile infection. Arch. Intern. Med. 172(2), 191-193 (2012).
37. Zipursky JS, Sidorsky TI, Freedman CA, Sidorsky MN, Kirkland KB. Patient attitudes toward the use of fecal microbiota transplantation in the treatment of recurrent Clostridium difficile infection. Clin. Infect. Dis. 55(2), 1652-1658 (2012).
38. Schwartz M et al. Am. J. Gastroenterol. (2013) (In Press).
39. Bennet JD, Brinkman M. Treatment of ulcerative colitis by implantation of normal colonic flora. Lancet 1(8630), 164 (1989).
40. Borody TJ, George L, Andrews P et al. Bowel-flora alteration: a potential cure for inflammatory bowel disease and irritable bowel syndrome? Med. J. Aust. 150(10), 604 (1989).
41. Borody TJ, Warren EF, Leis S, Surace R, Ashman O. Treatment of ulcerative colitis using fecal bacteriotherapy. J. Clin. Gastroenterol. 37(1), 42-47 (2003).
42. Anderson JL, Edney RJ, Whelan K. Systematic review: faecal microbiota transplantation in the management of inflammatory bowel disease. Aliment. Pharmacol. Ther. 36(6), 503-516 (2012).
43. Andrews PJ, Borody TJ. "Putting back the bugs": bacterial treatment relieves chronic constipation and symptoms of irritable bowel syndrome. Med. J. Aust. 159(9), 633-634 (1993).
44. Andrews PJ, Barnes P, Borody TJ. Chronic constipation reversed by restoration of bowel flora. A case and a hypothesis. Eur. J. Gastroenterol. Hepatol. 4, 245-247 (1992).
45. Collins SM, Bercik P. The relationship between intestinal microbiota and the central nervous system in normal gastrointestinal function and disease. Gastroenterology 136(6), 2003-2014 (2009).
46. Borody TJ, Leis S, Campbell J, Torres M, Nowak A. Fecal microbiota transplantation (FMT) in multiple sclerosis (MS). Am. J. Gastroenterol. S352 (2011).
47. Braak H, Rüb U, Gai WP, Del Tredici K. Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J. Neural. Transm. 110(5), 517-536 (2003).
48. Ananthaswamy A. Faecal transplant eases symptoms of Parkinson's. N. Sci. (2011).
49. Aroniadis OC, Brandt LJ. Fecal microbiota transplantation: past, present and future. Curr. Opin. Gastroenterol. 29(1), 79-84 (2013).
50. Na X, Kelly C. Probiotics in Clostridium difficile Infection. J. Clin. Gastroenterol. 45, S154-S158 (2011).
51. Johnson S, Maziade PJ, McFarland LV et al . Is primary prevention of Clostridium difficile infection possible with specific probiotics? Int. J. Infect. Dis. 16(11), e786-e792 (2012).
52. Surawicz CM, McFarland LV, Greenberg RN et al. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin. Infect. Dis. 31(4), 1012-1017 (2000).
53. Hempel S, Newberry SJ, Maher AR et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. JAMA 307(18), 1959-1969 (2012).
54. Gao XW, Mubasher M, Fang CY, Reifer C, Miller LE. Dose-response efficacy of a proprietary probiotic formula of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for antibiotic-associated diarrhea and Clostridium difficile-associated diarrhea prophylaxis in adult patients. Am. J. Gastroenterol. 105(7), 1636-1641 (2010).
55. Hickson M, D'Souza AL, Muthu N et al. Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial. BMJ 335(7610), 80 (2007).
56. Borody TJ, Campbell J. Fecal microbiota transplantation: current status and future directions. Expert. Rev. Gastroenterol. Hepatol. 5(6), 653-655 (2011).
57. Grehan MJ, Borody TJ, Leis SM, Campbell J, Mitchell H, Wettstein A. Durable alteration of the colonic microbiota by the administration of donor fecal flora. J. Clin. Gastroenterol. 44(8), 551-561 (2010).
58. Tannock GW, Munro K, Harmsen HJ, Welling GW, Smart J, Gopal PK. Analysis of the fecal microflora of human subjects consuming a probiotic product containing Lactobacillus rhamnosus DR20. Appl. Environ. Microbiol. 66(6), 2578-2588 (2000).
59. Cohen SH, Gerding DN, Johnson S et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect. Control Hosp. Epidemiol. 31(5), 431-455 (2010).
60. Johnston BC, Ma SS, Goldenberg JZ et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea: a systematic review and meta-analysis. Ann. Intern. Med. 157(12), 878-888 (2012).
61. Meijer BJ, Dieleman LA. Probiotics in the treatment of human inflammatory bowel diseases: update 2011. J. Clin. Gastroenterol. 45(Suppl.) S139-S144 (2011).
62. Tursi A, Brandimarte G, Giorgetti GM, Forti G, Modeo ME, Gigliobianco A. Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. Med. Sci. Monit. 10(11), PI126-PI131 (2004).
63. Matthes H, Krummenerl T, Giensch M et al. Treatment of mild to moderate acute attacks of distal ulcerative colitis with rectally-administered E. coli Nissle 1917: dose-dependent efficacy. Gastroenterology 130, A-119 (2006).
64. Tursi A, Brandimarte G, Papa A et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. Am. J. Gastroenterol. 105(10), 2218-2227 (2010).
65. Sood A, Midha V, Makharia GK et al. The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clin. Gastroenterol. Hepatol. 7(11), 1202-1209, (2009).
66. Miele E, Pascarella F, Giannetti E, Quaglietta L, Baldassano RN, Staiano A. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am. J. Gastroenterol. 104(2), 437-443 (2009).
67. Ritchie ML, Romanuk TN. A meta-analysis of probiotic efficacy for gastrointestinal diseases. PLoS ONE 7(4), e34938 (2012).
68. Gionchetti P, Rizzello F, Helwig U et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 124(5), 1202-1209 (2003).
69. Gionchetti P, Rizzello F, Venturi A et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 119(2), 305-309 (2000).
70. Hamilton-Miller J. Probiotics in the management of irritable bowel syndrome: a review of clinical trials. Microb. Ecol. Health Dis. 13, 212-216 (2001).
71. McFarland LV, Dublin S. Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World J. Gastroenterol. 14(17), 2650-2661 (2008).
72. Moayyedi P, Ford AC, Talley NJ et al. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut 59(3), 325-332 (2010).
73. Whelan K, Quigley EM. Probiotics in the management of irritable bowel syndrome and inflammatory bowel disease. Curr. Opin. Gastroenterol. 29(2), 184-189 (2013).
74. Ringel Y, Ringel-Kulka T. The rationale and clinical effectiveness of probiotics in irritable bowel syndrome. J. Clin. Gastroenterol. 45, S145-S148 (2011).
75. Whelan K. Probiotics and prebiotics in the management of irritable bowel syndrome: a review of recent clinical trials and systematic reviews. Curr. Opin. Clin. Nutr. Metab. Care 14(6), 581-587 (2011).
76. Huebner ES, Surawicz CM. Probiotics in the prevention and treatment of gastrointestinal infections. Gastroenterol. Clin. North. Am. 355-365 (2006).
77. Canducci F, Cremonini F, Armuzzi A et al. Probiotics and Helicobacter pylori eradication. Dig. Liver. Dis. 34(Suppl. 2), S81-S83 (2002).
78. Oláh A, Belágyi T, Issekutz A, Gamal ME, Bengmark S. Randomized clinical trial of specific lactobacillus and fibre supplement to early enteral nutrition in patients with acute pancreatitis. Br. J. Surg. 89(9), 1103-1107 (2002).
79. Besselink MG, Timmerman HM, Buskens E et al. Probiotic prophylaxis in patients with predicted severe acute pancreatitis (PROPATRIA): design and rationale of a double-blind, placebo-controlled randomised multicenter trial [ISRCTN38327949]. BMC Surg. 4, 12 (2004).
80. Besselink MG, van Santvoort HC, Buskens E et al. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet 371(9613), 651-659 (2008).
81. Bajaj JS, Saeian K, Christensen KM et al. Probiotic yogurt for the treatment of minimal hepatic encephalopathy. Am. J. Gastroenterol. 103(7), 1707-1715 (2008).
82. Liu JE, Zhang Y, Zhang J, Dong PL, Chen M, Duan ZP. Probiotic yogurt effects on intestinal flora of patients with chronic liver disease. Nurs. Res. 59(6), 426-432 (2010).
83. Karlsson C, Ahrne S, Molin G et al. Probiotic therapy to men with incipient arteriosclerosis initiates increased bacterial diversity in colon: a randomized controlled trial. Atherosclerosis 208(1), 228-233 (2010).
84. Naruszewicz M, Johansson ML, Zapolska-Downar D, Bukowska H. Effect of Lactobacillus plantarum 299v on cardiovascular disease risk factors in smokers. Am. J. Clin. Nutr. 76(6), 1249-1255 (2002).
85. Tang WH, Wang Z, Levison BS et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N. Engl. J. Med. 368(17), 1575-1584 (2013).
86. Ataie-Jafari A, Larijani B, Alavi Majd H, Tahbaz F. Cholesterol-lowering effect of probiotic yogurt in comparison with ordinary yogurt in mildly to moderately hypercholesterolemic subjects. Ann. Nutr. Metab. 54(1), 22-27 (2009).
87. Thompson LU, Jenkins DJ, Amer MA, Reichert R, Jenkins A, Kamulsky J. The effect of fermented and unfermented milks on serum cholesterol. Am. J. Clin. Nutr. 36(6), 1106-1111 (1982).
88. de Roos NM, Schouten G, Katan MB. Yoghurt enriched with Lactobacillus acidophilus does not lower blood lipids in healthy men and women with normal to borderline high serum cholesterol levels. Eur. J. Clin. Nutr. 53(4), 277-280 (1999).
89. Xiao JZ, Kondo S, Takahashi N et al. Effects of milk products fermented by Bifidobacterium longum on blood lipids in rats and healthy adult male volunteers. J. Dairy. Sci. 86(7), 2452-2461 (2003).
90. McNamara DJ, Lowell AE, Sabb JE. Effect of yogurt intake on plasma lipid and lipoprotein levels in normolipidemic males. Atherosclerosis 79(2-3), 167-171 (1989).
91. Kekkonen RA, Sysi-Aho M, Seppanen-Laakso T et al. Effect of probiotic Lactobacillus rhamnosus GG intervention on global serum lipidomic profiles in healthy adults. World J. Gastroenterol. 14(20), 3188-3194 (2008).
92. Fabian E, Elmadfa I. Influence of daily consumption of probiotic and conventional yoghurt on the plasma lipid profile in young healthy women. Ann. Nutr. Metab. 50(4), 387-393 (2006).
93. Guo Z, Liu XM, Zhang QX et al. Influence of consumption of probiotics on the plasma lipid profile: a meta-analysis of randomised controlled trials. Nutr. Metab. Cardiovasc. Dis. 21(11), 844-850 (2011).
94. Ejtahed HS, Mohtadi-Nia J, Homayouni-Rad A et al. Effect of probiotic yogurt containing Lactobacillus acidophilus and Bifidobacterium lactis on lipid profile in individuals with Type 2 diabetes mellitus. J. Dairy Sci. 94(7), 3288-3294 (2011).
95. Flint HJ. Obesity and the gut microbiota. J. Clin. Gastroenterol. 45, S128-S132 (2011).
96. DiBaise JK, Zhang H, Crowell MD, Krajmalnik-Brown R, Decker GA, Rittmann BE. Gut microbiota and its possible relationship with obesity. Mayo Clin. Proc. 83(4), 460-469 (2008).
97. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature 444(7122), 1022-1023 (2006).
98. Mathur R, Amichai M, Chua KS, Mirocha J, Barlow GM, Pimentel M. Methane and hydrogen positivity on breath test is associated with greater body mass index and body fat. J. Clin. Endocrinol. Metab. 98(4), E698-E702 (2013).
99. Ly NP, Litonjua A, Gold DR, Celedón JC. Gut microbiota, probiotics, and vitamin D: interrelated exposures influencing allergy, asthma, and obesity? J. Allergy Clin. Immunol. 127(5), 1087-1094; quiz 1095-1086 (2011).
100. Kalliomäki M, Collado MC, Salminen S, Isolauri E. Early differences in fecal microbiota composition in children may predict overweight. Am. J. Clin. Nutr. 87(3), 534-538 (2008).
101. Luoto R, Kalliomaki M, Laitinen K, Isolauri E. The impact of perinatal probiotic intervention on the development of overweight and obesity: follow-up study from birth to 10 years. Int. J. Obes. 34(10), 1531-1537 (2010).
102. Larsen N, Vogensen FK, van den Berg FW et al. Gut microbiota in human adults with Type 2 diabetes differs from non-diabetic adults. PLoS ONE, 5(2), e9085 (2010).
103. Ejtahed HS, Mohtadi-Nia J, Homayouni-Rad A, Niafar M, Asghari-Jafarabadi M, Mofid V. Probiotic yogurt improves antioxidant status in Type 2 diabetic patients. Nutrition 28(5), 539-543 (2012).
104. Vrieze A, Van Nood E, Holleman F et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 143(4), 913-916.e917 (2012).
105. Kawase M, He F, Kubota A et al. Effect of fermented milk prepared with two probiotic strains on Japanese cedar pollinosis in a double-blind placebo-controlled clinical study. Int. J. Food Microbiol. 128(3), 429-434 (2009).
106. Martinez-Canavate A, Sierra S, Lara-Villoslada F et al. A probiotic dairy product containing L. gasseri CECT5714 and L. coryniformis CECT5711 induces immunological changes in children suffering from allergy. Pediatr. Allergy Immunol. 20(6), 592-600 (2009).
107. Ozdemir O. Various effects of different probiotic strains in allergic disorders: an update from laboratory and clinical data. Clin. Exp. Immunol. 160(3), 295-304 (2010).
108. Morita H, He F, Kawase M et al. Preliminary human study for possible alteration of serum immunoglobulin E production in perennial allergic rhinitis with fermented milk prepared with Lactobacillus gasseri TMC0356. Microbiol. Immunol. 50(9), 701-706 (2006).
109. Olivares M, Díaz-Ropero MP, Gómez N et al. The consumption of two new probiotic strains, Lactobacillus gasseri CECT 5714 and Lactobacillus coryniformis CECT 5711, boosts the immune system of healthy humans. Int. Microbiol. 9(1), 47-52 (2006).
110. Jensen MP, Meldrum S, Taylor AL, Dunstan JA, Prescott SL. Early probiotic supplementation for allergy prevention: long-term outcomes. J. Allergy Clin. Immunol. 130(5), 1209-1211 e1205 (2012).
111. Kuitunen M, Kukkonen K, Juntunen-Backman K et al. Probiotics prevent IgE-associated allergy until age 5 years in cesarean-delivered children but not in the total cohort. J. Allergy Clin. Immunol. 123(2), 335-341 (2009).
112. Miraglia del Giudice M, De Luca MG, Capristo C. Probiotics and atopic dermatitis. A new strategy in atopic dermatitis. Dig. Liver Dis. 34(Suppl. 2), S68-S71 (2002).
113. Gerasimov SV, Vasjuta VV, Myhovych OO, Bondarchuk LI. Probiotic supplement reduces atopic dermatitis in preschool children: a randomized, double-blind, placebo-controlled, clinical trial. Am. J. Clin. Dermatol. 11(5), 351-361 (2010).
114. Drago L, Toscano M, De Vecchi E, Piconi S, Iemoli E. Changing of fecal flora and clinical effect of L. salivarius LS01 in adults with atopic dermatitis. J. Clin. Gastroenterol. 46, S56-S63 (2012).
115. Iemoli E, Trabattoni D, Parisotto S et al. Probiotics reduce gut microbial translocation and improve adult atopic dermatitis. J. Clin. Gastroenterol. 46, S33-S40 (2012).
116. Kim JY, Kwon JH, Ahn SH et al. Effect of probiotic mix (Bifidobacterium bifidum, Bifidobacterium lactis, Lactobacillus acidophilus) in the primary prevention of eczema: a double-blind, randomized, placebo-controlled trial. Pediatr. Allergy Immunol. 21(2 Pt 2), e386-e393 (2010).
117. Niers L, Martin R, Rijkers G et al. The effects of selected probiotic strains on the development of eczema (the PandA study). Allergy 64(9), 1349-1358 (2009).
118. Bosch M, Nart J, Audivert S et al. Isolation and characterization of probiotic strains for improving oral health. Arch. Oral Biol. 57(5), 539-549 (2012).
119. Flichy-Fernandez AJ, Alegre-Domingo T, Penarrocha-Oltra D, Penarrocha-Diago M. Probiotic treatment in the oral cavity: an update. Med. Oral Patol. Oral Cir. Bucal 15(5), e677-e680 (2010).
120. Näse L, Hatakka K, Savilahti E et al. Effect of long-term consumption of a probiotic bacterium, Lactobacillus rhamnosus GG, in milk on dental caries and caries risk in children. Caries Res. 35(6), 412-420 (2001).
121. Ahola AJ, Yli-Knuuttila H, Suomalainen T et al. Short-term consumption of probiotic-containing cheese and its effect on dental caries risk factors. Arch. Oral Biol. 47(11), 799-804 (2002).
122. Caglar E, Kuscu OO, Selvi Kuvvetli S, Kavaloglu Cildir S, Sandalli N, Twetman S. Short-term effect of ice-cream containing Bifidobacterium lactis Bb-12 on the number of salivary mutans streptococci and lactobacilli. Acta Odontol. Scand. 66(3), 154-158 (2008).
123. Caglar E, Kuscu OO, Cildir SK, Kuvvetli SS, Sandalli N. A probiotic lozenge administered medical device and its effect on salivary mutans streptococci and lactobacilli. Int. J. Paediatr. Dent. 18(1), 35-39 (2008).
124. Caglar E, Kavaloglu SC, Kuscu OO, Sandalli N, Holgerson PL, Twetman S. Effect of chewing gums containing xylitol or probiotic bacteria on salivary mutans streptococci and lactobacilli. Clin. Oral Investig. 11(4), 425-429 (2007).
125. Caglar E, Cildir SK, Ergeneli S, Sandalli N, Twetman S. Salivary mutans streptococci and lactobacilli levels after ingestion of the probiotic bacterium Lactobacillus reuteri ATCC 55730 by straws or tablets. Acta Odontol. Scand. 64(5), 314-318 (2006).
126. Caglar E, Sandalli N, Twetman S, Kavaloglu S, Ergeneli S, Selvi S. Effect of yogurt with Bifidobacterium DN-173 010 on salivary mutans streptococci and lactobacilli in young adults. Acta Odontol. Scand. 63(6), 317-320 (2005).
127. Chuang LC, Huang CS, Ou-Yang LW, Lin SY. Probiotic Lactobacillus paracasei effect on cariogenic bacterial flora. Clin. Oral Investig. 15(4), 471-476 (2011).
128. Dhingra K. Methodological issues in randomized trials assessing probiotics for periodontal treatment. J. Periodontal Res, 47(1), 15-26 (2012).
129. Krasse P, Carlsson B, Dahl C, Paulsson A, Nilsson A, Sinkiewicz G. Decreased gum bleeding and reduced gingivitis by the probiotic Lactobacillus reuteri. Swed. Dent. J. 30(2), 55-60 (2006).
130. Twetman S, Derawi B, Keller M, Ekstrand K, Yucel-Lindberg T, Stecksen-Blicks C. Short-term effect of chewing gums containing probiotic Lactobacillus reuteri on the levels of inflammatory mediators in gingival crevicular fluid. Acta Odontol. Scand. 67(1), 19-24 (2009).
131. Iwamoto T, Suzuki N, Tanabe K, Takeshita T, Hirofuji T. Effects of probiotic Lactobacillus salivarius WB21 on halitosis and oral health: an open-label pilot trial. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 110(2), 201-208 (2010).
132. Burton JP, Chilcott CN, Moore CJ, Speiser G, Tagg JR. A preliminary study of the effect of probiotic Streptococcus salivarius K12 on oral malodour parameters. J. Appl. Microbiol. 100(4), 754-764 (2006).
133. Keller MK, Bardow A, Jensdottir T, Lykkeaa J, Twetman S. Effect of chewing gums containing the probiotic bacterium Lactobacillus reuteri on oral malodour. Acta Odontol. Scand. 70(3), 246-250 (2012).
134. Hatakka K, Ahola AJ, Yli-Knuuttila H et al. Probiotics reduce the prevalence of oral candida in the elderly - a randomized controlled trial. J. Dent. Res. 86(2), 125-130 (2007).
135. Koll P, Mandar R, Marcotte H, Leibur E, Mikelsaar M, Hammarstrom L. Characterization of oral lactobacilli as potential probiotics for oral health. Oral Microbiol. Immunol. 23(2), 139-147 (2008).
136. Lamont RF, Sobel JD, Akins RA et al. The vaginal microbiome: new information about genital tract flora using molecular based techniques. BJOG 118(5), 533-549 (2011).
137. Antonio MA, Meyn LA, Murray PJ, Busse B, Hillier SL. Vaginal colonization by probiotic Lactobacillus crispatus CTV-05 is decreased by sexual activity and endogenous Lactobacilli. J. Infect. Dis. 199(10), 1506-1513 (2009).
138. Anukam K, Osazuwa E, Ahonkhai I et al. Augmentation of antimicrobial metronidazole therapy of bacterial vaginosis with oral probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14: randomized, double-blind, placebo controlled trial. Microbes Infect. 8(6), 1450-1454 (2006).
139. Anukam KC, Osazuwa E, Osemene GI, Ehigiagbe F, Bruce AW, Reid G. Clinical study comparing probiotic Lactobacillus GR-1 and RC-14 with metronidazole vaginal gel to treat symptomatic bacterial vaginosis. Microbes Infect. 8(12-13), 2772-2776 (2006).
140. Hemalatha R, Mastromarino P, Ramalaxmi BA, Balakrishna NV, Sesikeran B. Effectiveness of vaginal tablets containing lactobacilli versus pH tablets on vaginal health and inflammatory cytokines: a randomized, double-blind study. Eur. J. Clin. Microbiol. Infect. Dis. 31(11), 3097-3105 (2012).
141. Ehrstrom S, Daroczy K, Rylander E et al. Lactic acid bacteria colonization and clinical outcome after probiotic supplementation in conventionally treated bacterial vaginosis and vulvovaginal candidiasis. Microbes Infect. 12(10), 691-699 (2010).
142. Guillemard E, Tondu F, Lacoin F, Schrezenmeir J. Consumption of a fermented dairy product containing the probiotic Lactobacillus casei DN-114001 reduces the duration of respiratory infections in the elderly in a randomised controlled trial. Br. J. Nutr. 103(1), 58-68 (2010).
143. Guillemard E, Tanguy J, Flavigny A, de la Motte S, Schrezenmeir J. Effects of consumption of a fermented dairy product containing the probiotic Lactobacillus casei DN-114 001 on common respiratory and gastrointestinal infections in shift workers in a randomized controlled trial. J. Am. Coll. Nutr. 29(5), 455-468 (2010).
144. Leyer GJ, Li S, Mubasher ME, Reifer C, Ouwehand AC. Probiotic effects on cold and influenza-like symptom incidence and duration in children. 124, e172-e179 (2009).
145. Lin JS, Chiu YH, Lin NT et al. Different effects of probiotic species/strains on infections in preschool children: A double-blind, randomized, controlled study. Vaccine 27(7), 1073-1079 (2009).
146. Merenstein D, Murphy M, Fokar A et al. Use of a fermented dairy probiotic drink containing Lactobacillus casei (DN-114 001) to decrease the rate of illness in kids: the DRINK study. A patient-oriented, double-blind, cluster-randomized, placebo-controlled, clinical trial. Eur. J. Clin. Nutr. 64(7), 669-677 (2010).
147. Di Pierro F, Adami T, Rapacioli G, Giardini N, Streitberger C. Clinical evaluation of the oral probiotic Streptococcus salivarius K12 in the prevention of recurrent pharyngitis and/or tonsillitis caused by Streptococcus pyogenes in adults. Expert Opin. Biol. Ther. 13(3), 339-343 (2013).
148. Forestier C, Guelon D, Cluytens V, Gillart T, Sirot J, De Champs C. Oral probiotic and prevention of Pseudomonas aeruginosa infections: a randomized, double-blind, placebo-controlled pilot study in intensive care unit patients. Crit. Care. 12(3), R69(2008).
149. Morrow LE, Kollef MH, Casale TB. Probiotic prophylaxis of ventilator-associated pneumonia: a blinded, randomized, controlled trial. Am. J. Respir. Crit. Care Med. 182(8), 1058-1064 (2010).
150. Anukam KC, Osazuwa EO, Osadolor HB, Bruce AW, Reid G. Yogurt containing probiotic Lactobacillus rhamnosus GR-1 and L. reuteri RC-14 helps resolve moderate diarrhea and increases CD4 count in HIV/ AIDS patients. J. Clin. Gastroenterol. 42(3), 239-243 (2008).
151. Hummelen R, Changalucha J, Butamanya NL et al. Effect of 25 weeks probiotic supplementation on immune function of HIV patients. Gut Microbes 2(2), 80-85 (2011).
152. Arroyo R, Martin V, Maldonado A, Jimenez E, Fernandez L, Rodriguez JM. Treatment of infectious mastitis during lactation: antibiotics versus oral administration of Lactobacilli isolated from breast milk. Clin. Infect. Dis. 50(12), 1551-1558 (2010).
153. Jenks K, Stebbings S, Burton J, Schultz M, Herbison P, Highton J. Probiotic therapy for the treatment of spondyloarthritis: a randomized controlled trial. J. Rheumatol. 37(10), 2118-2125 (2010).
154. Messaoudi M, Violle N, Bisson JF, Desor D, Javelot H, Rougeot C. Beneficial psychological effects of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in healthy human volunteers. Gut Microbes 2(4), 256-261 (2011).
155. Messaoudi M, Lalonde R, Violle N et al. Assessment of psychotropic-like properties of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in rats and human subjects. Br. J. Nutr. 105(5), 755-764 (2011).